Gregory D. Ford

Gregory D. Ford


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
CMChristopher McGinley
Christopher McGinley
OAOyinkansola Adeyemi
Oyinkansola Adeyemi
OOOluwafayokemi Oyolola
Oluwafayokemi Oyolola
BFByron Ford
Byron Ford
GFGregory D. Ford
Gregory D. Ford
Ischemic stroke is a major cause of long-term disability and death, with oxidative stress contributing substantially to post-ischemic injury. Reperfusion restores oxygen supply but simultaneously increases reactive oxygen species (ROS), amplifying secondary neuronal damage. This study examined time-dependent changes in systemic thiol redox status following transient middle cerebral artery occlusion (tMCAO) in rats. Plasma concentrations of cysteine (CySH), cystine (CySS), glutathione (GSH), and glutathione disulfide (GSSG), along with corresponding CySS/CySH and GSSG/GSH ratios and redox potentials (Eh), were evaluated 24 and 48 h after occlusion. At 24 h, thiol concentrations and redox ratios showed no significant differences between sham and tMCAO groups. By 48 h, a marked oxidative shift emerged, characterized by reduced CySH, elevated GSSG, and significant increases in both CySS/CySH and GSSG/GSH ratios. Redox potentials also demonstrated substantial oxidation at this time point. These findings indicate that prolonged ischemia–reperfusion induces systemic oxidative stress, with plasma redox status serving as a sensitive indicator of reperfusion-related injury. The results underscore the plasma redox status as a potentially sensitive biomarker of reperfusion-induced oxidative injury and support the therapeutic value of targeting redox imbalance to mitigate oxidative damage following stroke.

2 June 2026 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
JNJessica M. Noll
Jessica M. Noll
CMChristopher McGinley
Christopher McGinley
CACatherine J. Augello
Catherine J. Augello
EKEsra Kürüm
Esra Kürüm
LPLiuliu Pan
Liuliu Pan
GFGregory D. Ford
Gregory D. Ford
Ischemic stroke remains a leading cause of death and long-term disability, yet effective treatments that promote recovery beyond the acute phase are lacking. Neuregulin-1 (NRG-1) has shown potent neuroprotective and anti-inflammatory properties in preclinical stroke models, with evidence of enhanced neuronal regeneration when administered after injury. To investigate the spatial mechanisms underlying its neuroregenerative therapeutic effects, we examined brain proteomic responses to post-ischemic NRG-1 treatment in mice using NanoString Digital Spatial Profiling (DSP). Adult C57BL/6 mice were subjected to photothrombotic middle cerebral artery occlusion (MCAO) and treated with NRG-1β (5 μg/kg/day) or vehicle at 24- and 48-h post-stroke. Brains were collected at 3 days post-ischemia for spatial proteomic analysis of 68 neural proteins across the ischemic core, peri-infarct tissue, and peri-infarct normal tissue (PiNT). While NRG-1 did not significantly alter overall neuronal death, it markedly reshaped the neuroregenerative milieu, upregulating myelin basic protein (MBP) and synaptophysin and attenuating inflammatory mediators (SPP1, P2RX7, and CD39). NRG-1 also enhanced expression of autophagy and mitophagy markers (ULK1, LC3B, ATG5, PINK1, and Park7), suggesting restoration of cellular clearance and mitochondrial quality control. Pathway and network analyses revealed activation of neuroregeneration, autophagy, and lysosomal biogenesis pathways, while suppressing neuroinflammatory signaling. These findings demonstrate that delayed NRG-1 therapy, even when initiated 24 h after stroke, induces early molecular programs that prime an anti-inflammatory and neuroregenerative environment. The results support further development of NRG-1 as a clinically translatable, multimodal therapy for extending the post-stroke treatment window and promoting functional recovery.

19 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
GFGregory D. Ford
Gregory D. Ford
CMChristopher McGinley
Christopher McGinley
OOOluwafayokemi Oyolola
Oluwafayokemi Oyolola
OAOyinkansola Adeyemi
Oyinkansola Adeyemi
MSMonique C. Surles-Zeigler
Monique C. Surles-Zeigler
BFByron Ford
Byron Ford
Neuroinflammation is a coordinated response to central nervous system injury and disease involving resident glia, neurons, the neurovascular unit, and infiltrating immune cells. Although transient inflammatory signaling supports host defense, debris clearance, and repair, persistent activation contributes to synaptic dysfunction, demyelination, blood–brain barrier disruption, and neuronal loss. Neuregulin-1 (NRG1), a pleiotropic epidermal growth factor family ligand, has emerged as a potential regulator of this balance. Through ErbB receptor complexes, particularly ErbB4-containing dimers, NRG1 influences neural development, myelination, synaptic function, cell survival, and inflammatory signaling. Experimental evidence indicates that NRG1 can restrain NF-κB-dependent transcription, alter microglial activation states, enhance alpha7 nicotinic acetylcholine receptor-associated anti-inflammatory signaling, support oligodendroglial lineage cells, and stabilize neurovascular integrity. However, these actions are context-dependent; in spinal nociceptive circuits, ErbB2-linked signaling can promote microglial activation and pain hypersensitivity. This review examines NRG1 isoform biology, ErbB receptor architecture, cellular targets, and disease-specific evidence across demyelinating disease, stroke, traumatic brain injury, neurodegeneration, cerebral malaria, sickle cell disease, and neuropathic pain. Translation will require isoform-specific, receptor-biased, and anatomically targeted approaches supported by rigorous in vivo validation and verified biomarkers.

13 March 2026 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
KBKimberly R. Bennett
Kimberly R. Bennett
MSMonique C. Surles-Zeigler
Monique C. Surles-Zeigler
CACatherine J. Augello
Catherine J. Augello
EAEtchi Ako
Etchi Ako
HOHakeem Omotayo
Hakeem Omotayo
BFByron Ford
Byron Ford
Introduction: Neuregulin-1 (NRG-1) is a growth factor that has been investigated for its neuroprotective properties following ischemic stroke. While NRG-1 has shown considerable promise in reducing neuronal damage, the molecular mechanisms underlying its protective effects remain unclear. This study aimed to examine the impact of NRG-1 treatment on ischemia-induced gene expression following permanent middle cerebral artery occlusion (MCAO) in rats. Methods: Rats were treated with either NRG-1 or vehicle then sacrificed 3 and 12 h after permanent MCAO. RNA isolated from the peri-infarct cortex (ischemic penumbra) was hybridized to an Affymetrix Rat Genome 2.0 ST Microarray Gene Chip. Gene expression was analyzed using the Affymetrix Transcriptome Analysis Console (TAC) 4.0 software and the STRING Protein–Protein Interaction Networks database. Results: NRG-1 treatment upregulated transcriptional programs promoting cell survival and anti-inflammatory signaling. CREB1 and FOXO1 transcription factor pathways, which are associated with anti-inflammatory signaling, cell proliferation, reduced apoptosis, and decreased oxidative stress, were upregulated. Consistent with the transcriptomic findings, Luminex multiplex transcription factor assays validated the increased CREB1 and FOXO1 activity in NRG-1-treated MCAO brains. Discussion: These findings provide novel insight into the molecular mechanisms by which NRG-1 mediates neuroprotection, highlighting its role in activating transcriptional programs that promote neuronal survival and resilience following ischemic injury.

14 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GFGregory D. Ford
Gregory D. Ford
CMChristopher McGinley
Christopher McGinley
OOOluwafayokemi Oyolola
Oluwafayokemi Oyolola
OAOyinkansola Adeyemi
Oyinkansola Adeyemi
MSMonique C. Surles-Zeigler
Monique C. Surles-Zeigler
BFByron Ford
Byron Ford
Neuroinflammation is a coordinated response to central nervous system injury and disease involving resident glia, neurons, the neurovascular unit, and infiltrating immune cells. Although transient inflammatory signaling supports host defense, debris clearance, and repair, persistent activation contributes to synaptic dysfunction, demyelination, blood-brain barrier disruption, and neuronal loss. Neuregulin-1 (NRG1), a pleiotropic epidermal growth factor family ligand, has emerged as a potential regulator of this balance. Through ErbB receptor complexes, particularly ErbB4-containing dimers, NRG1 influences neural development, myelination, synaptic function, cell survival, and inflammatory signaling. Experimental evidence indicates that NRG1 can restrain NF-κB -dependent transcription, alter microglial activation states, enhance alpha7 nicotinic acetylcholine receptor-associated anti-inflammatory signaling, support oligodendroglial lineage cells, and stabilize neurovascular integrity. However, these actions are context dependent; in spinal nociceptive circuits, ErbB2-linked signaling can promote microglial activation and pain hypersensitivity. This review examines NRG1 isoform biology, ErbB receptor architecture, cellular targets, and disease-specific evidence across demyelinating disease, stroke, traumatic brain injury, neurodegeneration, cerebral malaria, sickle cell disease, and neuropathic pain. Translation will require isoform-specific, receptor-biased, and anatomically targeted approaches supported by rigorous in vivo validation and verified biomarkers.